Holen Sie sich die Stockscreener-App
325.77
1.95%
8.6822
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Connor Clark & Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal shares hold as Cowen maintains price target on new data - Investing.com Canada
Madrigal Pharmaceuticals (FRA:YDO1) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH - Scrip
(11/18/24) MDGL: A Promising Play in the Weight Loss Drug Space - Moneyshow.com
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in Madrigal Phar - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc - GuruFocus.com
(MDGL) Trading Report - Stock Traders Daily
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Fiera Capital Corp Sells 3,535 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock - Investing.com India
3 High Growth Tech Stocks Leading The US Market - Simply Wall St
B. Riley Has Bullish Estimate for MDGL FY2024 Earnings - MarketBeat
Madrigal Pharmaceuticals (FRA:YDO1) Current Ratio : 5.98 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - The Manila Times
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Analysts Offer Predictions for MDGL Q1 Earnings - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares - Investing.com
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares By Investing.com - Investing.com UK
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
MDGL (Madrigal Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Check Out What Whales Are Doing With MDGL - Benzinga
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectat - GuruFocus.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance
FY2028 Earnings Forecast for MDGL Issued By Leerink Partnrs - MarketBeat
Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN
MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa
Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN
Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily
Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Earnings Results, Beats Expectations By $2.02 EPS - MarketBeat
MDGL stock soars to 52-week high, reaching $299.99 - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume Following Earnings Beat - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):